Entities / Company
Aquestive (United States).
company in Warren Township, United States
- Reports this week
- 0
- Active events
- 0
- Connections
- 41
What's happening
Reports per dayLast 90 days
90 days agoDrag either end to show only events that began in that periodToday
One to three months ago
Gone quiet
No new reports in 90+ days-
Bratton Capital Management is the largest shareholder, followed by BlackRock and The Vanguard Group, Inc., in a company.Speculative2 reports
-
Aquestive (AQST) benefits from Trump-era tariffs, with FDA approval driving positive outlook and analysts reaffirming Buy ratings.Speculative1 report1 development inside
-
Zacks Investment Research provided stock analysis and earnings reports for Tenet Healthcare and Aquestive on June 24, 2025.Speculative1 report
-
Aquestive is seeking FDA approval for its product Anaphylm, with data presented at a conference in Chicago.Some support3 reports
-
Aquestive follows the company on LinkedIn and its management participates in the forum.Speculative1 report
-
Aquestive, a specialty pharmaceutical company, outperformed the S&P 500 gain this year.Some support2 reports1 development inside
-
Aquestive, a specialty pharmaceutical company, seeks international regulatory approval in Canada.Some support1 report
-
Aquestive announced on August 15, 2025, that its forecast growth exceeded the industry average for the pharmaceuticals sector.Some support2 reports
-
Aquestive is seeking FDA approval for a product while also filing registration statements with the SEC for a stock offering.Some support1 report
-
Aquestive received $75m in strategic funding from RTW Investments for its Anaphylm prodrug candidate.Some support1 report
-
Aquestive participated in several healthcare investor conferences, including Cantor and Wells Fargo, on August 26, 2025.Some support1 report
No events began in the chosen period. Widen it, or reset.
Around Aquestive (United States) this week
News at the entities that move Aquestive (United States) most-
FDA StructuralGeneric medicine services are seeking approval for launch from the FDA.Moves Aquestive (United States)
-
Dan Barber StructuralDan Barber discusses how global culinary trends are influencing the development of chefs.Moves Aquestive (United States)
-
Leerink partners TransactionalAnalyst firm set price targets for Leerink partners' client, Twist Bioscience, on June 26, 2026. Concurrently, the CEO sold shares due to tax withholding obligations.Moves Aquestive (United States)
-
LinkedIn Mentioned togetherBoth LinkedIn and Google are currently being utilized as platforms for news distribution.Moves Aquestive (United States)
Connections
The 5 strongest of 41, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
Daniel Barber Structural
Daniel Barber holds the role of Chief Executive Officer for Aquestive.
-
FDA Structural
Aquestive's commercial viability and product launch are structurally dependent on formal regulatory approval from the FDA.
-
Dan Barber Structural
Dan Barber serves as the CEO and President of Aquestive.
-
Leerink partners Transactional
Leerink partners jointly managed a stock offering for Aquestive.
-
LinkedIn Mentioned together
Aquestive uses LinkedIn as a platform to follow and gather information.
History
Events by the month they beganJune 2026
12 events- Aquestive, led by Dan Barber, received a determination from the FDA regarding its drug development process.
- Bratton Capital Management is the largest shareholder, followed by BlackRock and The Vanguard Group, Inc., in a company.
- Aquestive (AQST) benefits from Trump-era tariffs, with FDA approval driving positive outlook and analysts reaffirming Buy ratings.
- Zacks Investment Research provided stock analysis and earnings reports for Tenet Healthcare and Aquestive on June 24, 2025.
- Aquestive is seeking FDA approval for its product Anaphylm, with data presented at a conference in Chicago.
- Aquestive follows the company on LinkedIn and its management participates in the forum.
- Aquestive, a specialty pharmaceutical company, outperformed the S&P 500 gain this year.
- Aquestive, a specialty pharmaceutical company, seeks international regulatory approval in Canada.
- Aquestive announced on August 15, 2025, that its forecast growth exceeded the industry average for the pharmaceuticals sector.
- Aquestive is seeking FDA approval for a product while also filing registration statements with the SEC for a stock offering.
- Aquestive received $75m in strategic funding from RTW Investments for its Anaphylm prodrug candidate.
- Aquestive participated in several healthcare investor conferences, including Cantor and Wells Fargo, on August 26, 2025.